Effects of denosumab on bone mineral density in men receiving androgen deprivation therapy for prostate cancer.

ABSTRACT:

Purpose

In a recently completed 3-year, randomized, double-blind study, denosumab, a fully human monoclonal antibody against receptor activator of nuclear factor kappaB ligand, significantly increased bone mineral density and decreased new vertebral fractures in men receiving androgen deprivation therapy for prostate cancer. We conducted subgroup analyses to evaluate the relationships between subject characteristics and the effects of denosumab on bone mineral density at multiple skeletal sites.

Materials and methods

A total of 1,468 subjects were randomized 1:1 to receive 60 mg subcutaneous denosumab every 6 months or placebo for 36 months. In these analyses we evaluated the effects of denosumab on bone mineral density at the lumbar spine, total hip and distal 1/3 radius (s

SUBMITTER: Smith MR 

PROVIDER: S-EPMC2900763 | biostudies-literature | 2009 Dec

REPOSITORIES: biostudies-literature